The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Explore the growing U.S. Zilbrysq (Zilucoplan) market, projected to expand at a CAGR of 21.64% post-FDA approval for anti-AChR antibody-positive generalized myasthenia gravis (gMG). The subcutaneous ...